menu ☰
menu ˟

DAPA-HF: Dapagliflozin’s HF benefits consistent regardless of age, symptom severity

17 Nov 2019
PHILADELPHIA — Treatment with the SGLT2 inhibitor dapagliflozin reduced risk for CV death and worsening HF across a broad spectrum of age, independent of symptomatic impairment at baseline, according to two new post-hoc analyses of the DAPA-HF tria...

Click here to view the full article which appeared in

Please note

The news articles accessible on the Health Well website have been compiled from various sources that are not controlled by the Institute of Public Health in Ireland (IPH). IPH is therefore not responsible for the content of external websites and the inclusion of a link to an external website from the Health Well should not be understood to be an endorsement of that website.